Reducing high blood pressure with appropriate medications will help prevent complications. What causes diabetic retinopathy? The best results occur when sight is still normal. Eventually, diabetic retinopathy, glaucoma or both can lead to complete vision loss. After light passes through the cornea, it travels through a space called the anterior chamber which is filled with a protective fluid called the aqueous humour, through the pupil which is a hole in the iris, the coloured part of the eye, and then through a lens that performs more focusing. The lei is conducting and supporting research that seeks better ways to detect, treat, and prevent vision loss in people with diabetes. American Academy of Ophthalmology Symptoms, diagnosis and treatment of diabetic retinopathy along with diagrams and video clips You may have heard that diabetes causes eye problems and may lead to blindness. Abnormalities in these vessels are a major cause of retinopathy.
“These findings are clinically relevant, as cardiovascular disease is the leading cause of death in people with type 2 diabetes and new treatment options that can also reduce the risk of cardiovascular events are needed.” In this outcomes trial, from an overall mean baseline of 8.7%, semaglutide 0.5 mg and 1.0 mg significantly reduced HbA1cby -1.1% and -1.4% vs -0.4% for both placebo 0.5 mg and 1.0 mg at 104 weeks, when added to standard of care. About Ideras Third Generation Antisense Platform (3ga) Ideras Proprietary Third-generation Antisense (3ga) Platform Technology Is Focused On Silencing The Mrna Associated With Disease Causing Genes. | Advice For Your EyesIn addition, from a mean baseline of 92.1 kg, adults treated with semaglutide 0.5 mg and 1.0 mg experienced superior and sustained weight loss of -3.6 kg and -4.9 kg, vs -0.7 kg for placebo 0.5 mg and -0.5 kg for placebo 1.0 mg. Fewer serious adverse events were seen with semaglutide vs placebo; however, treatment discontinuation due to adverse events was more frequent with semaglutide, mainly due to gastrointestinal events. The incidence of pancreatitis was lower with semaglutide vs placebo. In terms of microvascular complications, significantly fewer people treated with semaglutide (62 [3.8%]) vs placebo (100 [6.1%]) had new onset or worsening nephropathy while significantly more people treated with semaglutide (50 [3.0%]) vs placebo (29 [1.8%]) experienced diabetic retinopathy complications. “The results of SUSTAIN 6 support the strong potential of once-weekly semaglutide in type 2 diabetes treatment and we look forward to regulatory submission later this year,” said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. “The SUSTAIN 6 results further strengthen the clinical evidence for the Novo Nordisk GLP-1 receptor agonist portfolio with the finding of additional benefits beyond glycaemic control and weight loss in adults with type 2 diabetes at high cardiovascular risk.” About semaglutide Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner, while decreasing appetite and food intake.With SUSTAIN 6, semaglutide, administered subcutaneously once-weekly, has completed six phase 3a clinical trials for the treatment of adults with type 2 diabetes. About SUSTAIN 6 SUSTAIN 6 was a multicentre, international, randomised, double-blind, placebo-controlled pre-marketing CV outcomes trial (CVOT) investigating the long-term effects of semaglutide (0.5 mg and 1.0 mg) administered once-weekly, compared to placebo, when added to standard of care, in adults with type 2 diabetes at high risk of CV events. Standard of care included lifestyle modifications, glucose-lowering treatments and CV medications. The trial was initiated in February 2013 and randomised 3,297 adults with type 2 diabetes from 20 countries that were treated for 104 weeks. SUSTAIN 6 is the first dedicated pre-marketing CVOT in a type 2 diabetes population to report data. no dataSUSTAIN 6 was designed to assess non-inferiority, i.e. demonstrate no increased risk of major CV events vs placebo, when added to standard of care.
For the original version including any supplementary images or video, visit http://www.prnewswire.com/news-releases/semaglutide-reduced-major-cardiovascular-events-by-26-in-adults-with-type-2-diabetes-at-high-cardiovascular-risk-593658161.html